Peginterferon alfa-2a - Rhein Minapharm Biogenetics

Drug Profile

Peginterferon alfa-2a - Rhein Minapharm Biogenetics

Alternative Names: Hansenula-derived peginterferon alpha-2a; PEG-IFN alpha-2a - Rhein Minapharm Biogenetics; PEG-interferon alpha-2a - Rhein Minapharm Biogenetics; Peginterferon alpha-2a - Rhein Minapharm Biogenetics; Reiferon Retard

Latest Information Update: 21 Feb 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rhein Minapharm Biogenetics
  • Class Antivirals; Interferons; Polyethylene glycols
  • Mechanism of Action Immunostimulants; Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 31 Jan 2005 Launched for Hepatitis C in Egypt (SC)
  • 28 Dec 2004 Registered for Hepatitis C in Egypt (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top